Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range

Edina C. Wang, Rebecca Sinnott, Michael E. Werner, Manish Sethi, Angelique W. Whitehurst, Andrew Z. Wang

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Current preclinical evaluations of nanoparticle taxanes have focused on the effect of nanoparticle size and shape on the efficacy and toxicity. It is generally assumed that nanoparticle therapeutics have the same cellular response on tumor and normal cells as their small molecule counterparts. Here, we show that nanoparticle taxanes can mediate cellular effects distinct from that of small molecule taxanes at the sub-therapeutic dose range. Cells that are exposed to two polymeric nanoparticle formulations of docetaxel were found to undergo a different cell cycle and cell fate than those of cells that were exposed to small molecule docetaxel. Our results suggest that nanoparticle formulation of therapeutics can affect the therapeutic effect of its cargo. From the Clinical Editor: This study investigates the differences between subtherapeutic doses of docetaxel applied as small molecules vs. nanoparticle formulations, demonstrating differential effects on the cell cycle and overall cell fate. The study suggests that the carrier may change the therapeutic effects of its cargo, which has important implications on future research.

Original languageEnglish (US)
Pages (from-to)321-328
Number of pages8
JournalNanomedicine: Nanotechnology, Biology, and Medicine
Volume10
Issue number2
DOIs
StatePublished - Feb 2014

Fingerprint

docetaxel
Nanoparticles
Molecules
Taxoids
Therapeutic Uses
Therapeutics
Cell Cycle
Cells
Toxicity
Tumors

Keywords

  • Controlled drug release
  • Cytotoxicity
  • Drug delivery
  • Nanomedicine
  • Nanoparticle

ASJC Scopus subject areas

  • Molecular Medicine
  • Bioengineering
  • Biomedical Engineering
  • Materials Science(all)
  • Medicine (miscellaneous)
  • Pharmaceutical Science

Cite this

Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range. / Wang, Edina C.; Sinnott, Rebecca; Werner, Michael E.; Sethi, Manish; Whitehurst, Angelique W.; Wang, Andrew Z.

In: Nanomedicine: Nanotechnology, Biology, and Medicine, Vol. 10, No. 2, 02.2014, p. 321-328.

Research output: Contribution to journalArticle

Wang, Edina C. ; Sinnott, Rebecca ; Werner, Michael E. ; Sethi, Manish ; Whitehurst, Angelique W. ; Wang, Andrew Z. / Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range. In: Nanomedicine: Nanotechnology, Biology, and Medicine. 2014 ; Vol. 10, No. 2. pp. 321-328.
@article{0b2168e07f074c668bb3c4ccc59bf128,
title = "Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range",
abstract = "Current preclinical evaluations of nanoparticle taxanes have focused on the effect of nanoparticle size and shape on the efficacy and toxicity. It is generally assumed that nanoparticle therapeutics have the same cellular response on tumor and normal cells as their small molecule counterparts. Here, we show that nanoparticle taxanes can mediate cellular effects distinct from that of small molecule taxanes at the sub-therapeutic dose range. Cells that are exposed to two polymeric nanoparticle formulations of docetaxel were found to undergo a different cell cycle and cell fate than those of cells that were exposed to small molecule docetaxel. Our results suggest that nanoparticle formulation of therapeutics can affect the therapeutic effect of its cargo. From the Clinical Editor: This study investigates the differences between subtherapeutic doses of docetaxel applied as small molecules vs. nanoparticle formulations, demonstrating differential effects on the cell cycle and overall cell fate. The study suggests that the carrier may change the therapeutic effects of its cargo, which has important implications on future research.",
keywords = "Controlled drug release, Cytotoxicity, Drug delivery, Nanomedicine, Nanoparticle",
author = "Wang, {Edina C.} and Rebecca Sinnott and Werner, {Michael E.} and Manish Sethi and Whitehurst, {Angelique W.} and Wang, {Andrew Z.}",
year = "2014",
month = "2",
doi = "10.1016/j.nano.2013.07.012",
language = "English (US)",
volume = "10",
pages = "321--328",
journal = "Nanomedicine: Nanotechnology, Biology, and Medicine",
issn = "1549-9634",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Differential cell responses to nanoparticle docetaxel and small molecule docetaxel at a sub-therapeutic dose range

AU - Wang, Edina C.

AU - Sinnott, Rebecca

AU - Werner, Michael E.

AU - Sethi, Manish

AU - Whitehurst, Angelique W.

AU - Wang, Andrew Z.

PY - 2014/2

Y1 - 2014/2

N2 - Current preclinical evaluations of nanoparticle taxanes have focused on the effect of nanoparticle size and shape on the efficacy and toxicity. It is generally assumed that nanoparticle therapeutics have the same cellular response on tumor and normal cells as their small molecule counterparts. Here, we show that nanoparticle taxanes can mediate cellular effects distinct from that of small molecule taxanes at the sub-therapeutic dose range. Cells that are exposed to two polymeric nanoparticle formulations of docetaxel were found to undergo a different cell cycle and cell fate than those of cells that were exposed to small molecule docetaxel. Our results suggest that nanoparticle formulation of therapeutics can affect the therapeutic effect of its cargo. From the Clinical Editor: This study investigates the differences between subtherapeutic doses of docetaxel applied as small molecules vs. nanoparticle formulations, demonstrating differential effects on the cell cycle and overall cell fate. The study suggests that the carrier may change the therapeutic effects of its cargo, which has important implications on future research.

AB - Current preclinical evaluations of nanoparticle taxanes have focused on the effect of nanoparticle size and shape on the efficacy and toxicity. It is generally assumed that nanoparticle therapeutics have the same cellular response on tumor and normal cells as their small molecule counterparts. Here, we show that nanoparticle taxanes can mediate cellular effects distinct from that of small molecule taxanes at the sub-therapeutic dose range. Cells that are exposed to two polymeric nanoparticle formulations of docetaxel were found to undergo a different cell cycle and cell fate than those of cells that were exposed to small molecule docetaxel. Our results suggest that nanoparticle formulation of therapeutics can affect the therapeutic effect of its cargo. From the Clinical Editor: This study investigates the differences between subtherapeutic doses of docetaxel applied as small molecules vs. nanoparticle formulations, demonstrating differential effects on the cell cycle and overall cell fate. The study suggests that the carrier may change the therapeutic effects of its cargo, which has important implications on future research.

KW - Controlled drug release

KW - Cytotoxicity

KW - Drug delivery

KW - Nanomedicine

KW - Nanoparticle

UR - http://www.scopus.com/inward/record.url?scp=84893352321&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84893352321&partnerID=8YFLogxK

U2 - 10.1016/j.nano.2013.07.012

DO - 10.1016/j.nano.2013.07.012

M3 - Article

C2 - 23916886

AN - SCOPUS:84893352321

VL - 10

SP - 321

EP - 328

JO - Nanomedicine: Nanotechnology, Biology, and Medicine

JF - Nanomedicine: Nanotechnology, Biology, and Medicine

SN - 1549-9634

IS - 2

ER -